Click Here to return To Results

 

Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial JAMA 330:512-517, 510, Sims,J.R.,et al, 2023 See this aricle in Pubmed Article Abstract Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium tau and in the combined low/medium and high tau pathology population.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction Alzheimer's disease Alzheimer's disease,treatment of amyloid amyloid beta protein amyloid plaques donanemab efficacy monoclonal antibodies safety TRAILBLAZER-ALZ trial treatment of neurologic disorder

Click Here to return To Results